Diligence memo · auto-generated · as of July 2, 2026
Accipiter Biosciences Inc.
Accipiter Biosciences Inc. looks over-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Accipiter Biosciences Inc. operates in Biotech / Pharma, based in SEATTLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Accipiter Biosciences Inc. has raised $14M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $14M on 2024-05-17.
Most recent recorded round closed around 2024-05-17.
Valuation (modeled)modeled
Provath models Accipiter Biosciences Inc. at approximately $75M (range $15M–$167M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.93× the median modeled value of Series A Biotech / Pharma companies in 2022–2024 (21 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 2.1 yr ago; this sector typically re-raises about every 15 months.
Slightly overdue versus sector cadence.
The last round was 1.7× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 67% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 64% of those peers.
Closest niche peers: Laxmi Therapeutic Devices, Inc., Nanospectra Biosciences Inc, Ten Bay Bio, Inc., Genomic Life, Inc., NJ BIO, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.